1. Vitamin D Related/Nuclear Receptor Autophagy Apoptosis Anti-infection Metabolic Enzyme/Protease
  2. Estrogen Receptor/ERR Autophagy Mitophagy Apoptosis HIV Parasite Endogenous Metabolite
  3. Kaempferol

Kaempferol  (Synonyms: 山奈酚; Kempferol; Robigenin)

目录号: HY-14590 纯度: 99.92%
COA 产品使用指南

Kaempferol (Kempferol) 在乳腺癌细胞中抑制雌激素受体 (estrogen receptor α) 表达,在胶质母细胞瘤细胞和肺癌细胞中,通过激活 MEK-MAPK 诱导细胞凋亡。Kaempferol 可用于乳腺癌研究。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Kaempferol Chemical Structure

Kaempferol Chemical Structure

CAS No. : 520-18-3

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥450
In-stock
50 mg ¥405
In-stock
100 mg ¥750
In-stock
200 mg ¥900
In-stock
500 mg ¥2000
In-stock
1 g   询价  
5 g   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Kaempferol:

MCE 顾客使用本产品发表的 35 篇科研文献

WB

    Kaempferol purchased from MCE. Usage Cited in: Biomed Pharmacother. 2023 Jan;157:114087.  [Abstract]

    Kaempferol (KPF; 100 μM; pretreat for 1 h) significantly inhibits the Doxorubicin (DOX)-induced increased expression of apoptosis-related proteins including cleaved-caspase3, p-P53, and reverses the decline of the ratio of Bcl2 to Bax, indicating that Kaempferol suppresses apoptosis in tubular epithelial cells.
    • 生物活性

    • 实验参考方法

    • 纯度 & 产品资料

    • 参考文献

    生物活性

    Kaempferol (Kempferol), a flavonoid found in many edible plants, inhibits estrogen receptor α expression in breast cancer cells and induces apoptosis in glioblastoma cells and lung cancer cells by activation of MEK-MAPK. Kaempferol can be uesd for the research of breast cancer[1][2][3][4].

    IC50 & Target[1]

    ERα

     

    Human Endogenous Metabolite

     

    细胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    A549 IC50
    > 1 x 10-4 M
    Compound: 7
    Cytotoxicity against human A549 cells after 72 hrs by XTT assay
    Cytotoxicity against human A549 cells after 72 hrs by XTT assay
    [PMID: 20619940]
    A549 IC50
    > 10 μM
    Compound: 2
    Cytotoxicity against human A549 cells measured after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells measured after 48 hrs by MTT assay
    [PMID: 33979163]
    A549 IC50
    > 10 μM
    Compound: 5
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    [PMID: 28165740]
    A549 IC50
    > 20 μg/mL
    Compound: Kaempferol
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 21106454]
    B16 IC50
    20 μM
    Compound: 10
    Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells after 72 hrs
    Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells after 72 hrs
    [PMID: 19615910]
    B16 IC50
    53.7 μM
    Compound: 11
    Cytotoxicity against mouse B16 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against mouse B16 cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 25659770]
    B16-4A5 IC50
    25 μM
    Compound: 16
    Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells after 72 hrs
    Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells after 72 hrs
    [PMID: 20189399]
    B16-4A5 IC50
    88 μM
    Compound: 10
    Inhibition of theophylline-stimulated mouse B16-4A5 cell proliferation assessed as cell viability after 68 hrs by WST8 assay
    Inhibition of theophylline-stimulated mouse B16-4A5 cell proliferation assessed as cell viability after 68 hrs by WST8 assay
    [PMID: 19615910]
    BEAS-2B IC50
    0.35 mM
    Compound: 2
    Cytotoxicity against human BEAS-2B cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human BEAS-2B cells assessed as reduction in cell viability after 24 hrs by MTT assay
    [PMID: 33231455]
    BGC-823 IC50
    > 10 μM
    Compound: 2
    Cytotoxicity against human BGC-823 cells measured after 48 hrs by MTT assay
    Cytotoxicity against human BGC-823 cells measured after 48 hrs by MTT assay
    [PMID: 33979163]
    BT-549 IC50
    > 10 μM
    Compound: 5
    Cytotoxicity against human BT549 cells after 48 hrs by SRB assay
    Cytotoxicity against human BT549 cells after 48 hrs by SRB assay
    [PMID: 28165740]
    BV-2 IC50
    8.86 μM
    Compound: 5
    Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitrite production after 24 hrs by Griess assay
    Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitrite production after 24 hrs by Griess assay
    [PMID: 28165740]
    Ca9-22 IC50
    > 20 μg/mL
    Compound: Kaempferol
    Cytotoxicity against human Ca9-22 cells by MTT assay
    Cytotoxicity against human Ca9-22 cells by MTT assay
    [PMID: 21106454]
    CHO-K1 IC50
    0.24 mM
    Compound: 2
    Cytotoxicity against CHO-K1 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against CHO-K1 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    [PMID: 33231455]
    CWR22R IC50
    > 40 μM
    Compound: 19
    Antiproliferative activity against human 22Rv1 cells incubated up to 144 hrs by Coulter particle count and size analyzer
    Antiproliferative activity against human 22Rv1 cells incubated up to 144 hrs by Coulter particle count and size analyzer
    [PMID: 22789812]
    HCC1937 IC50
    > 10 μM
    Compound: 2
    Cytotoxicity against human HCC1937 cells measured after 48 hrs by MTT assay
    Cytotoxicity against human HCC1937 cells measured after 48 hrs by MTT assay
    [PMID: 33979163]
    HCT-116 IC50
    > 10 μM
    Compound: 2
    Cytotoxicity against human HCT-116 cells measured after 48 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells measured after 48 hrs by MTT assay
    [PMID: 33979163]
    HEK293 IC50
    1.2 μM
    Compound: 7h
    Inhibition of NOX4 expressed in HEK293 FS cells assessed as H2O2 production by H2O2/Tyr/LPO assay
    Inhibition of NOX4 expressed in HEK293 FS cells assessed as H2O2 production by H2O2/Tyr/LPO assay
    [PMID: 20731357]
    HEK293 IC50
    3.9 μM
    Compound: 21
    Inhibition of human TRPC5 expressed in HEK293 cells assessed as reduction in gadolinium-induced calcium entry after 30 mins by fluo-4 dye based fluorescence assay
    Inhibition of human TRPC5 expressed in HEK293 cells assessed as reduction in gadolinium-induced calcium entry after 30 mins by fluo-4 dye based fluorescence assay
    [PMID: 30943030]
    HeLa IC50
    > 1 x 10-4 M
    Compound: 7
    Cytotoxicity against human HeLa cells after 72 hrs by XTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by XTT assay
    [PMID: 20619940]
    HeLa IC50
    2.4 μg/mL
    Compound: 6
    Antiallergic activity in Ca(2+)-stimulated differentiated human HeLa cells assessed as inhibition of cys-leukotriene release after 6 days by ELISA
    Antiallergic activity in Ca(2+)-stimulated differentiated human HeLa cells assessed as inhibition of cys-leukotriene release after 6 days by ELISA
    [PMID: 19942440]
    Hep 3B2 IC50
    17.74 μg/mL
    Compound: Kaempferol
    Cytotoxicity against human Hep3B cells by MTT assay
    Cytotoxicity against human Hep3B cells by MTT assay
    [PMID: 21106454]
    HepG2 IC50
    > 10 μM
    Compound: 2
    Cytotoxicity against human HepG2 cells measured after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells measured after 48 hrs by MTT assay
    [PMID: 33979163]
    HepG2 IC50
    > 20 μg/mL
    Compound: Kaempferol
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    [PMID: 21106454]
    HepG2 IC50
    > 400 μM
    Compound: 33
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    [PMID: 21726077]
    HepG2 EC50
    7.74 μM
    Compound: Kaempferol
    Antioxidant activity in human HepG2 cells assessed as decrease in fluorescence level after 2.5 hrs measured every 5 mins for 1 hr by DCFH-DA staining based fluorescence assay
    Antioxidant activity in human HepG2 cells assessed as decrease in fluorescence level after 2.5 hrs measured every 5 mins for 1 hr by DCFH-DA staining based fluorescence assay
    [PMID: 26974372]
    HepG2 IC50
    9.64 μM
    Compound: 5
    Inverse agonist activity at human GAL4-DBD-fused ERRalpha-LBD transfected in human HepG2 cells assessed as disruption of interaction with PGC-1alpha after 24 hrs by dual luciferase reporter gene assay
    Inverse agonist activity at human GAL4-DBD-fused ERRalpha-LBD transfected in human HepG2 cells assessed as disruption of interaction with PGC-1alpha after 24 hrs by dual luciferase reporter gene assay
    [PMID: 23656512]
    HT-29 IC50
    > 1 x 10-4 M
    Compound: 7
    Cytotoxicity against human HT-29 cells after 72 hrs by XTT assay
    Cytotoxicity against human HT-29 cells after 72 hrs by XTT assay
    [PMID: 20619940]
    Huh-7 CC50
    > 50 μM
    Compound: 26
    Cytotoxicity against human Huh7.5.1 cells by MTT assay
    Cytotoxicity against human Huh7.5.1 cells by MTT assay
    [PMID: 22445328]
    J774.2 IC50
    53.67 μM
    Compound: 1
    Cytotoxicity against BALB/c mouse J774.2 cells after 72 hrs by trypan blue assay
    Cytotoxicity against BALB/c mouse J774.2 cells after 72 hrs by trypan blue assay
    [PMID: 19489596]
    Jurkat IC50
    10.5 μM
    Compound: Kaempferol
    Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method
    Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method
    [PMID: 30776692]
    Jurkat IC50
    11 μM
    Compound: Kaempferol
    Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method
    Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method
    [PMID: 30776692]
    L929 EC50
    20 μM
    Compound: kaempferol
    Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining
    Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining
    [PMID: 9287415]
    L929 EC50
    25 μM
    Compound: kaempferol
    Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay
    Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay
    [PMID: 9287415]
    MCF7 IC50
    > 10 μM
    Compound: 2
    Cytotoxicity against human MCF7 cells measured after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells measured after 48 hrs by MTT assay
    [PMID: 33979163]
    MCF7 IC50
    > 20 μg/mL
    Compound: Kaempferol
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    [PMID: 21106454]
    MCF7 IC50
    50 μM
    Compound: Kaempferol
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay
    [PMID: 33257172]
    MCF7 IC50
    6.2 μM
    Compound: 12
    Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining
    Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining
    [PMID: 21354800]
    MDA-MB-231 IC50
    > 20 μg/mL
    Compound: Kaempferol
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    [PMID: 21106454]
    MDCK CC50
    > 300 μM
    Compound: 3
    Cytotoxicity against MDCK cells after 48 hrs by MTT assay
    Cytotoxicity against MDCK cells after 48 hrs by MTT assay
    [PMID: 19729316]
    MDCK IC50
    4.7 μM
    Compound: 12
    Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining
    Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining
    [PMID: 21354800]
    Monocyte IC50
    2.7 μM
    Compound: kaempferol
    Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs
    Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs
    [PMID: 8882428]
    Monocyte IC50
    20 μM
    Compound: Kaempferol
    Inhibition of TNFalpha expression in LPS-stimulated human monocytes treated 30 mins before LPS challenge measured after 14 hrs by ELISA
    Inhibition of TNFalpha expression in LPS-stimulated human monocytes treated 30 mins before LPS challenge measured after 14 hrs by ELISA
    [PMID: 10096854]
    MV4-11 GI50
    3.34 μM
    Compound: 5
    Cytotoxicity against human MV4-11 cells harboring FLT3 mutation after 72 hrs by tetrazolium based Ez CyTox cell viability assay
    Cytotoxicity against human MV4-11 cells harboring FLT3 mutation after 72 hrs by tetrazolium based Ez CyTox cell viability assay
    [PMID: 23411073]
    Peritoneal macrophage IC50
    29 μM
    Compound: 5; kp19
    Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method
    Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method
    [PMID: 27955927]
    Platelet IC50
    > 50 μg/mL
    Compound: Kaempferol
    Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry
    Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry
    [PMID: 21106454]
    Platelet IC50
    3.55 μg/mL
    Compound: Kaempferol
    Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry
    Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry
    [PMID: 21106454]
    RAW264.7 IC50
    13.4 μM
    Compound: 5; kp19
    Inhibition of LPS-stimulated nitric oxide production in mouse RAW264.7 cells by Griess method
    Inhibition of LPS-stimulated nitric oxide production in mouse RAW264.7 cells by Griess method
    [PMID: 27955927]
    RAW264.7 IC50
    13.4 μM
    Compound: Kaempferol
    Inhibition of LPS-stimulated nitric oxide production in rat RAW264.7 cells pretreated for 2 hrs followed by LPS-stimulation after 16 hrs by Griess assay
    Inhibition of LPS-stimulated nitric oxide production in rat RAW264.7 cells pretreated for 2 hrs followed by LPS-stimulation after 16 hrs by Griess assay
    [PMID: 28662961]
    RAW264.7 IC50
    15 μM
    Compound: 5; kp19
    Inhibition of LPS/INF-gamma-stimulated nitric oxide production in mouse RAW264.7 cells measured after 16 hrs
    Inhibition of LPS/INF-gamma-stimulated nitric oxide production in mouse RAW264.7 cells measured after 16 hrs
    [PMID: 27955927]
    RAW264.7 IC50
    17 μM
    Compound: 5; kp19
    Inhibition of LPS/INF-gamma-stimulated nitric oxide production in mouse RAW264.7 cells by Griess method
    Inhibition of LPS/INF-gamma-stimulated nitric oxide production in mouse RAW264.7 cells by Griess method
    [PMID: 27955927]
    RAW264.7 IC50
    60.2 μM
    Compound: 7
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method
    [PMID: 21353543]
    RAW264.7 IC50
    80.3 μM
    Compound: 7
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs
    [PMID: 21353543]
    RS4-11 GI50
    > 50 μM
    Compound: 5
    Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by tetrazolium based Ez CyTox cell viability assay
    Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by tetrazolium based Ez CyTox cell viability assay
    [PMID: 23411073]
    Sf21 IC50
    > 100 μM
    Compound: 6
    Inhibition of human recombinant COX2 expressed in insect Sf21 cells by EIA assay
    Inhibition of human recombinant COX2 expressed in insect Sf21 cells by EIA assay
    [PMID: 17378609]
    SK-MEL-2 IC50
    > 10 μM
    Compound: 5
    Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay
    Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay
    [PMID: 28165740]
    SK-OV-3 IC50
    > 10 μM
    Compound: 5
    Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay
    Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay
    [PMID: 28165740]
    体外研究
    (In Vitro)

    Kaempferol 还通过抑制 Src 激酶和下调 NFκB 通路来抑制白细胞介素 4 和环加氧酶 2 的表达,从而具有抗炎作用。山奈酚还可有效抑制卵巢癌细胞的血管生成和诱导细胞凋亡[1]。Kaempferol 是一种天然黄酮类化合物,广泛分布于水果和蔬菜中,前瞻性研究表明,几十年来,食用 Kaempferol 可显著降低美国女护士患卵巢癌的风险。经过 24 小时的处理后,Kaempferol 对所有 3 种受试卵巢癌细胞的增殖产生显著的浓度依赖性抑制。在 40 μM 或更高浓度的处理时观察到这种抑制作用[2]。Kaempferol 是一种类黄酮,广泛存在于多种植物衍生食品和传统药物中使用的叶子中。Kaempferol 显著抑制 NADPH 氧化酶活性。山奈酚通过直接结合 NADPH 氧化酶来减少活性氧 (ROS)。Kaempferol 通过降低 CAMKII 氧化来防止 Ang II 诱导的窦房结细胞死亡[3]。10 -20 μM Kaempferol 剂量依赖性地抑制其在致敏 RBL-2H3 细胞中的释放。当将 10 -20 μM Kaempferol 补充到 DNP-BSA 攻击的 RBL-2H3 细胞中 15 分钟时,Syk 和 PLCγ 的激活被高度减弱。当向 DNP-BSA 攻击的 RBL-2H3 细胞中加入 ≥10 μM Kaempferol 60 分钟时,COX2 诱导减少[4]

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    体内研究
    (In Vivo)

    COX2 诱导在 BSA 攻击的 BALB/c 小鼠的气道中得到证实。观察到未处理的对照小鼠的气道中缺乏 COX2。小鼠吸入 BSA 导致小鼠气道中 COX2 诱导增强 (深棕色染色),这可通过口服山奈酚逆转。在 BSA 攻击的小鼠中,观察到明显的杯状细胞增生和上皮增厚。当 BSA 攻击小鼠补充 20 mg/kg Kaempferol 时,上皮增厚完全消失[4]

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    分子量

    286.24

    Formula

    C15H10O6

    CAS 号
    性状

    固体

    颜色

    Light yellow to yellow

    中文名称

    山奈酚

    结构分类
    初始来源
    运输条件

    Room temperature in continental US; may vary elsewhere.

    储存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    溶解性数据
    细胞实验: 

    DMSO 中的溶解度 : 20 mg/mL (69.87 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

    H2O 中的溶解度 : < 0.1 mg/mL (insoluble)

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 3.4936 mL 17.4679 mL 34.9357 mL
    5 mM 0.6987 mL 3.4936 mL 6.9871 mL
    查看完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
    储备液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C储存时,请在1年内使用, -20°C储存时,请在6个月内使用。

    • 摩尔计算器

    • 稀释计算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    质量
    =
    浓度
    ×
    体积
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    浓度 (start)

    C1

    ×
    体积 (start)

    V1

    =
    浓度 (final)

    C2

    ×
    体积 (final)

    V2

    动物实验:

    请根据您的 实验动物和给药方式 选择适当的溶解方案。

    以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
    ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用
    以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

    • 方案 一

      请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2 mg/mL (6.99 mM); 澄清溶液

      此方案可获得 ≥ 2 mg/mL(饱和度未知)的澄清溶液。

      1 mL 工作液为例,取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;再向上述体系中加入 50 μL Tween-80,混合均匀;然后再继续加入 450 μL 生理盐水 定容至 1 mL

      生理盐水的配制:将 0.9 g 氯化钠,溶解于 ddH₂O 并定容至 100 mL,可以得到澄清透明的生理盐水溶液。
    • 方案 二

      请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2 mg/mL (6.99 mM); 澄清溶液

      此方案可获得 ≥ 2 mg/mL(饱和度未知)的澄清溶液。

      1 mL 工作液为例,取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中,混合均匀。

      2 g SBE-β-CD(磺丁基醚 β-环糊精)粉末定容于 10 mL 的生理盐水中,完全溶解至澄清透明。

    以下溶解方案,请直接配制工作液。建议现用现配,在短期内尽快用完。 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶。

    • 方案 一

      请依序添加每种溶剂: 50% PEG300    50% Saline

      Solubility: 10 mg/mL (34.94 mM); 悬浊液; 超声助溶

    • 方案 二

      请依序添加每种溶剂: 0.5% CMC/saline water

      Solubility: 5 mg/mL (17.47 mM); 悬浊液; 超声助溶

    动物溶解方案计算器
    请输入动物实验的基本信息:

    给药剂量

    mg/kg

    动物的平均体重

    g

    每只动物的给药体积

    μL

    动物数量

    由于实验过程有损耗,建议您多配一只动物的量
    请输入您的动物体内配方组成:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    如果您的动物是免疫缺陷鼠或者体弱鼠,建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
    方案所需 助溶剂 包括:DMSO ,均可在 MCE 网站选购。 Tween 80,均可在 MCE 网站选购。
    计算结果
    工作液所需浓度 : mg/mL
    储备液配制方法 : mg 药物溶于 μL  DMSO(母液浓度为 mg/mL)。
    您所需的储备液浓度超过该产品的实测溶解度,以下方案仅供参考,如有需要,请与 MCE 中国技术支持联系。
    动物实验体内工作液的配制方法 : 取 μL DMSO 储备液,加入 μL  μL ,混合均匀至澄清,再加 μL Tween 80,混合均匀至澄清,再加 μL 生理盐水
    连续给药周期超过半月以上,请谨慎选择该方案。
    请确保第一步储备液溶解至澄清状态,从左到右依次添加助溶剂。您可采用超声加热 (超声清洗仪,建议频次 20-40 kHz),涡旋吹打等方式辅助溶解。
    纯度 & 产品资料

    纯度: 99.92%

    参考文献
    Kinase Assay
    [3]

    Right atria or sinus nodal cells are homogenized in lysis buffer consisting of (50 mM Tris-HCl pH 7.5, 100 mM KCl, 1 mM ethylenediamine tetraacetic acid, 1 mM ethylene glycol tetraacetic acid, 1 mM dithiothreitol, 0.1 mM phenylmethylsulfonyl fluoride, 0.5 mM Benzamidine, 20 mg/L Leupeptin, 20 mM sodium pyrophosphate, 50 mM NaF, and 50 mM sodium β-glycerophosphate), and total protein content is determined by the Bradford assay. Caspase-3 activity is determined by EnzChek Caspase-3 Assay Kit[3].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Assay
    [2]

    Ovarian cancer cells are seeded in 96-well plates at 2000 cells/well and incubated overnight before treatment with 0-160 μM Kaempferol for 24 hours in triplicates. The medium is removed, and the plates are freeze-thawed to lyse cells. Each well is added with 200 μL 1× CyQUANT cell lysis buffer containing 5x SYBR Green I and incubated at room temperature (RT) for 5 minutes. The reaction (50 μL) is transferred to PCR strip tubes and the fluorescent signal is measured at 90°C with a real-time Chromo4 PCR instrument. To ensure that cell proliferation assays are performed within a linear range of cell numbers, a standard curve is generated by seeding different amount of OVCAR-3 cells (based on counting with a hemacytometer) in a 96-well plate, and measuring genomic DNA abundance after overnight incubation. Three independent experiments are performed and data is pooled for statistical analysis[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [4]

    Mice[4]
    Three-week-old male BALB/c mice are randomly assigned to the four treatment groups as follows (n=8 per group). (1) PBS-sensitized mice; (2) BSA-sensitized mice; (3) BSA-sensitized and 10 mg/kg Kaempferol-administered mice; and (4) BSA-sensitized and 20 mg/kg Kaempferol-administered mice. Mice are given a commercial mouse chow diet containing 20.5% protein, 3.5% fat, 8% fiber, 8% ash, and 0.5% phosphorus and are allowed access to food and water ad libitum. The mice are kept under a 12 h light and dark cycle at 23±1°C with 50%±5% relative humidity in specific pathogen-free conditions. Mice are allowed to become accustomed to their surroundings for one week before starting the allergic experiments. Sensitization of all experimental mice is carried out by subcutaneous injection with 20 μg BSA in 30 μL PBS and 50 μL Imject Alum on days 0 and 14. The control mice are injected with a combination of 50 μL PBS and 50 μL Imject Alum without BSA. On days 28, 29, and 30, only the experimental mice sensitized to BSA are subject to inhalation of 5% BSA, while control mice are challenged with 5% PBS for 20 min in a plastic chamber connected to a Medel aerosol nebulizer. All mice are sacrificed 24 h after the last challenge. Whole blood samples are directly used to measure the contents of eosinophils, basophils and neutrophils. The right lung is stored in 4% paraformaldehyde until use.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    参考文献

    完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
    储备液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C储存时,请在1年内使用, -20°C储存时,请在6个月内使用。

    可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.4936 mL 17.4679 mL 34.9357 mL 87.3393 mL
    5 mM 0.6987 mL 3.4936 mL 6.9871 mL 17.4679 mL
    10 mM 0.3494 mL 1.7468 mL 3.4936 mL 8.7339 mL
    15 mM 0.2329 mL 1.1645 mL 2.3290 mL 5.8226 mL
    20 mM 0.1747 mL 0.8734 mL 1.7468 mL 4.3670 mL
    25 mM 0.1397 mL 0.6987 mL 1.3974 mL 3.4936 mL
    30 mM 0.1165 mL 0.5823 mL 1.1645 mL 2.9113 mL
    40 mM 0.0873 mL 0.4367 mL 0.8734 mL 2.1835 mL
    50 mM 0.0699 mL 0.3494 mL 0.6987 mL 1.7468 mL
    60 mM 0.0582 mL 0.2911 mL 0.5823 mL 1.4557 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的产品:

    Your information is safe with us. * Required Fields.

       产品名称:

     

    * 需求量:

    * 客户姓名:

     

    * Email:

    * 电话:

     

    * 公司或机构名称:

       留言给我们:

    Bulk Inquiry

    Inquiry Information

    产品名称:
    Kaempferol
    目录号:
    HY-14590
    需求量: